Korea South
Panolos Bioscience, founded in 2019 and based in Korea South, positions itself as a frontrunner in the biopharma, biotechnology, and pharmaceutical industries, with a distinct focus on multi-specific biotherapeutics.
The company is pioneering in structure-based protein design, concentrating on anti-angiogenic therapies for cancer, autoimmune, and rare diseases. Their proprietary "Alpha(α)-ART (Anti-angiogenesis-based Artifact Re-targeting Tri-specific) technology" leverages a VEGF receptor backbone to enhance therapeutic efficacy. The upcoming Phase I trial for PB101, manufactured by Samsung Biologics, underlines their advanced capabilities.
Strategic collaborations include a development partnership with Kelun-Biotech for PB203, and a strategic alliance with Chime Biologics. Having raised $18 million in Series A from investors like UTC 2019 BioVentureFund and JL Partners, Panolos seeks $20 million in a Series B Bridge round to further their innovative pipeline, which targets PD-L1, EGFR, and TGF-beta(b).
